Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meggie Beckley

Physician Assistant, Medical Indianapolis, IN Physician Assistant

NPI 1730343849 CMS profile 10489268

202 N Illinois St, Ste 165, Indianapolis, IN 46204

Open in the dashboard

General payments

$124,527

436 records reported · program years 2021–2025

Research payments

$280

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meggie Beckley of Indianapolis, IN is reported in the CMS Open Payments database as having received $124,527 across 436 general payments and $280 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,429 100
2024 General $46,846 156
2023 General $30,640 109
2022 General $17,509 62
2022 Research $280 1
2021 General $3,102 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meggie Beckley
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Meggie Beckley were reported at $26,429. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Meggie Beckley Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,102 $156 $41–$563 $132
2022 $17,509 $185 $55–$649 $149
2023 $30,640 $199 $58–$717 $160
2024 $46,846 $206 $62–$740 $164
2025 $26,429 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $124,242 429 payments
  2. Revance Therapeutics, Inc. $134 1 payment
  3. Merz North America, Inc. $69 2 payments
  4. MML US, Inc. $22 1 payment
  5. Tonix Pharmaceuticals, Inc. $21 1 payment
  6. Abbott Laboratories $20 1 payment
  7. Galderma Laboratories, L.P. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $80,092 55 payments
  2. Travel and Lodging $33,688 180 payments
  3. Food and Beverage $10,702 200 payments
  4. Education $45 1 payment
Products named General payments · program years 2021–2025
  1. SYNCHROMEDII $88,319 296 payments
  2. INTELLIS ADAPTIVESTIM $22,252 85 payments
  3. VANTA ADAPTIVESTIM $9,395 28 payments
  4. SYNCHROMED $3,002 8 payments
  5. RESTORESENSORSURESCAN $280 2 payments
  6. OPTISPHERE $213 1 payment
  7. SYNCRA CRT-P $190 1 payment
  8. DAXXIFY $134 1 payment
  9. Vanta $100 1 payment
  10. Xeomin $69 2 payments
  11. Other $101 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Medtronic, Inc. $280 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

296

Median for Physician Assistant: 241

Drug cost

$5,858

Median for Physician Assistant: $4,110

Branded share of claims

29.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 55 $1,563
Gabapentin Generic 65 $1,206
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 40 $1,007
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 46 $893
Cyclobenzaprine Hcl Generic 27 $563
Tizanidine Hcl Generic 23 $219
Oxycodone Hcl Generic 12 $205
Tramadol Hcl Generic 11 $119
Meloxicam Generic 17 $82

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$3,587

Medicare's payments for the services billed

Medicare patients

54

Average age 67

Services billed

95

41 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 56%
Diabetes 46%
Ischemic heart disease 37%
Chronic kidney disease 31%
Osteoporosis 28%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

437 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record